Encaleret for Hypocalcemia

(CALIBRATE Trial)

This trial tests a new treatment called encaleret for individuals with Autosomal Dominant Hypocalcemia Type 1 (ADH1), a condition that lowers calcium levels in the blood. Researchers aim to evaluate the effectiveness and safety of encaleret compared to the usual care, which includes calcium supplements and active Vitamin D. Participants with specific gene changes related to ADH1 who have experienced its symptoms may be suitable candidates. The goal is to determine if encaleret can better manage calcium levels in these patients. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

Yes, you may need to stop taking certain medications. If you are on thiazide diuretics, phosphate binders, magnesium or potassium supplements, or potassium-sparing diuretics, you will need to discontinue them before starting the trial. There are specific timeframes for stopping these medications, such as at least 14 days for thiazides and at least one day for phosphate binders.

Yes, you may need to stop taking certain medications. If you are on thiazide diuretics, you must stop them at least 14 days before a specific visit. You also need to stop phosphate binders (except calcium salts), magnesium or potassium supplements, and potassium-sparing diuretics before starting the trial.

Research shows that encaleret is generally safe for people. Studies have found that encaleret helps maintain balanced calcium levels in individuals with Autosomal Dominant Hypocalcemia Type 1 (ADH1). In earlier research, participants used encaleret for up to 18 months without major problems. No serious side effects were reported, indicating its safety for long-term use. These findings provide promising evidence about the safety of encaleret for those considering participation in a clinical trial.¹²³⁴⁵

Unlike the standard of care for hypocalcemia, which involves calcium supplements and active Vitamin D, encaleret offers a unique approach by directly adjusting calcium levels in the body. Researchers are excited about encaleret because it targets the underlying regulation of calcium, potentially allowing for more precise control of calcium levels. This could lead to more effective management of hypocalcemia symptoms with fewer side effects compared to traditional treatments.

Research has shown that encaleret, which participants in this trial may receive, may help treat Autosomal Dominant Hypocalcemia Type 1 (ADH1). In one study, encaleret helped maintain stable calcium levels in patients over time. This stability suggests it could be a reliable way to manage the condition. Reports noted that patients taking encaleret experienced significant improvements in their mineral balance. Overall, these findings support the idea that encaleret can be effective for people with ADH1.¹²⁶⁷⁸